Seeking Alpha

More on Bristol-Myers (BMY -2.5%) Q3: swings to net loss of $711M from $969M last year, due to...

More on Bristol-Myers (BMY -2.5%) Q3: swings to net loss of $711M from $969M last year, due to $1.8B charge for failed hepatitis C treatment. Earnings also hurt by Plavix sales plunging 96% to $64M following loss of patent protection, with sales of Avapro hit for the same reason. Guides to upper end of EPS 2012 forecast of $1.90-$2 vs. consensus of $1.92. Revenue seen at $17.4B-$17.8B vs $17.86B.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs